|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/20 Iovance Biotherapeutics, Inc. 10-Q 6/30/20 63:7.7M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.27M
2: EX-10.3 Material Contract HTML 38K
3: EX-10.4 Material Contract HTML 51K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 20K
14: R1 Document And Entity Information HTML 71K
15: R2 Condensed Consolidated Balance Sheets HTML 90K
16: R3 Condensed Consolidated Balance Sheets HTML 40K
(Parenthetical)
17: R4 Condensed Consolidated Statements of Operations HTML 40K
18: R5 Condensed Consolidated Statements of Comprehensive HTML 29K
Loss
19: R6 Condensed Consolidated Statements of Stockholders' HTML 80K
Equity
20: R7 Condensed Consolidated Statements of Cash Flows HTML 84K
21: R8 General Organization and Business HTML 29K
22: R9 Summary of Significant Accounting Policies HTML 143K
23: R10 Cash Equivalents and Short-Term Investments HTML 108K
24: R11 Balance Sheet Components HTML 37K
25: R12 Stockholders' Equity HTML 30K
26: R13 Stock Based Compensation HTML 71K
27: R14 Licenses and Agreements HTML 38K
28: R15 Legal Proceedings HTML 37K
29: R16 Leases HTML 141K
30: R17 Related Party Transactions HTML 22K
31: R18 Subsequent Event HTML 21K
32: R19 Summary of Significant Accounting Policies HTML 173K
(Policies)
33: R20 Summary of Significant Accounting Policies HTML 127K
(Tables)
34: R21 Cash Equivalents and Short-Term Investments HTML 108K
(Tables)
35: R22 Balance Sheet Components (Tables) HTML 36K
36: R23 Stock Based Compensation (Tables) HTML 64K
37: R24 Leases (Tables) HTML 129K
38: R25 General Organization and Business (Details) HTML 44K
39: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, HTML 38K
Cash equivalents and Restricted Cash (Details)
40: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Loss HTML 28K
per share (Details)
41: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 25K
value (Details)
42: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Stock-based compensation expense (Details)
43: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Stock-based compensation by instrument (Details)
44: R31 Cash Equivalents and Short-Term Investments HTML 26K
(Details)
45: R32 Cash Equivalents and Short-Term Investments - HTML 23K
Short-term investments (Details)
46: R33 CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Cost HTML 33K
and fair value (Details)
47: R34 Balance Sheet Components (Details) HTML 34K
48: R35 Stockholders' Equity (Details) HTML 90K
49: R36 STOCK BASED COMPENSATION - Stock Options (Details) HTML 59K
50: R37 STOCK BASED COMPENSATION - Assumptions (Details) HTML 31K
51: R38 STOCK BASED COMPENSATION - Additional information HTML 104K
(Details)
52: R39 Licenses and Agreements (Details) HTML 69K
53: R40 Legal Proceedings (Details) HTML 51K
54: R41 LEASES - Company's right-of-use asset and lease HTML 28K
liabilities (Details)
55: R42 LEASES - components of lease expenses (Details) HTML 42K
56: R43 LEASES - maturities of the Company's operating HTML 45K
lease liabilities (Details)
57: R44 LEASES - Additional information (Details) HTML 142K
58: R45 RELATED PARTY TRANSACTIONS - Additional HTML 35K
information (Details)
59: R46 Subsequent Event (Details) HTML 23K
61: XML IDEA XML File -- Filing Summary XML 106K
13: XML XBRL Instance -- iova-20200630x10q_htm XML 1.90M
60: EXCEL IDEA Workbook of Financial Reports XLSX 88K
9: EX-101.CAL XBRL Calculations -- iova-20200630_cal XML 113K
10: EX-101.DEF XBRL Definitions -- iova-20200630_def XML 491K
11: EX-101.LAB XBRL Labels -- iova-20200630_lab XML 881K
12: EX-101.PRE XBRL Presentations -- iova-20200630_pre XML 744K
8: EX-101.SCH XBRL Schema -- iova-20200630 XSD 133K
62: JSON XBRL Instance as JSON Data -- MetaLinks 254± 388K
63: ZIP XBRL Zipped Folder -- 0001104659-20-091526-xbrl Zip 351K
Exhibit 31.2
CERTIFICATION
I, Michael C. Swartzburg, Interim Principal Financial Officer of Iovance Biotherapeutics, Inc., certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Iovance Biotherapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: August 6, 2020 | By: | |
| | |
| | VP, Finance (Interim Principal Financial Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/6/20 | 8-K | ||
| For Period end: | 6/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Iovance Biotherapeutics, Inc. 10-K 12/31/23 95:11M Toppan Merrill Bridge/FA 2/28/23 Iovance Biotherapeutics, Inc. 10-K 12/31/22 78:10M Toppan Merrill Bridge/FA 2/24/22 Iovance Biotherapeutics, Inc. 10-K 12/31/21 79:10M Toppan Merrill Bridge/FA 2/25/21 Iovance Biotherapeutics, Inc. 10-K 12/31/20 84:11M Toppan Merrill Bridge/FA 2/09/21 Iovance Biotherapeutics, Inc. 424B5 1:799K Toppan Merrill/FA 11/05/20 Iovance Biotherapeutics, Inc. 10-Q 9/30/20 62:7.8M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/09/20 Iovance Biotherapeutics, Inc. 8-K:5,9 6/08/20 12:480K Toppan Merrill/FA 5/27/20 Iovance Biotherapeutics, Inc. 8-K:5,8,9 5/27/20 12:508K Toppan Merrill/FA 2/25/20 Iovance Biotherapeutics, Inc. 10-K 12/31/19 88:11M Toppan Merrill/FA |